A UT Health San Antonio-led discovery could redefine drug discovery by turning IV medications into orally administered treatments for brain cancer, Alzheimer’s disease, and other complex conditions. The new strategy uses a protein receptor called CD36 to efficiently deliver large molecules into cells.
SourceUniversity of Texas Health Science Center at San Antonio·JournalCell·TypeExperimental study·DateApr 21, 2025
Apple iPhone 17 Pro
Apple iPhone 17 Pro delivers top performance and advanced cameras for field documentation, data collection, and secure research communications.
Insilico Medicine's Pharma.AI Day 2025 will showcase the latest AI breakthroughs and updates, including precision target discovery engine PandaOmics and generative biologics platform Generative Biologics. The company aims to accelerate drug discovery and advance life sciences research with its proprietary platform.
The University of Missouri is partnering with a consortium to design and license a new research reactor, NextGen MURR, which will produce critical medical isotopes for cancer treatment. The project aims to enhance Missouri's role as a leader in nuclear science and medical research.
Insilico Medicine is a pioneer in generative AI-driven healthcare, showcasing its Pharma.AI platform and pipeline portfolio featuring IND clearance molecules. The company will share insights at Abu Dhabi Global Health Week panel discussions, focusing on longevity and precision health.
A new USC-led study using fMRI reveals the neural mechanisms that contribute to urinary incontinence in stroke survivors. The research found significant differences in brain activity during voluntary versus involuntary bladder contractions, presenting potential pathways for targeted therapies.
SourceKeck School of Medicine of USC·JournalStroke·TypeExperimental study·DateApr 10, 2025
Researchers created a promising approach that augments LLMs with graph-based models to generate molecules with desired properties. The method generates molecules with better matching user specifications and valid synthesis plans, outperforming existing LLM-based approaches.
SourceMassachusetts Institute of Technology·DateApr 9, 2025
Kestrel 3000 Pocket Weather Meter
Kestrel 3000 Pocket Weather Meter measures wind, temperature, and humidity in real time for site assessments, aviation checks, and safety briefings.
Researchers discovered a mechanism that harnesses immune cells to produce opioids, potentially alleviating chronic pain. Estrogen and progesterone drive this process, which could lead to more effective treatments for women experiencing pain after menopause.
SourceUniversity of California - San Francisco·JournalScience·DateApr 3, 2025
The Ontario Institute for Cancer Research has announced support for five research teams developing new cancer drugs with improved efficacy and reduced side effects. The funded projects will focus on harnessing new insights about cancer biology to stop cancer from spreading and overcome treatment resistance.
SourceOntario Institute for Cancer Research·DateApr 3, 2025
Engineers at University of Bristol spin-out company Impulsonics have created a technology that can move cells using acoustic waves, enabling critical lab tasks to be carried out on a benchtop device. This innovation has the potential to accelerate drug discovery and unlock personalized medicine screening in clinics.
SourceUniversity of Bristol·JournalScience·DateApr 3, 2025
The Mount Sinai Hospital has launched an AI Small Molecule Drug Discovery Center to revolutionize the creation of life-saving medicines. The center will use cutting-edge AI to design and optimize novel therapeutics with unprecedented speed and precision.
SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·DateApr 2, 2025
Researchers created a thromboinflammation-on-a-chip model that can sustain blood clots for several months and track treatment options. This model reveals critical information on clot resolution and suggests new drug combinations to protect endothelial function in patients with sickle cell disease.
SourceEmory Health Sciences·JournalNature·DateApr 2, 2025
SAMSUNG T9 Portable SSD 2TB
SAMSUNG T9 Portable SSD 2TB transfers large imagery and model outputs quickly between field laptops, lab workstations, and secure archives.
A University of Iowa-led study has revealed the unexpected structure adopted by the DNA repair protein RAD52 as it binds and protects replicating DNA in dividing cells. This understanding may help researchers develop new anti-cancer drugs targeting RAD52.
SourceUniversity of Iowa Health Care·JournalNature·TypeExperimental study·DateApr 2, 2025
Researchers developed new AI models, InstaNovo and InstaNovo+, to vastly improve accuracy and discovery in protein science. These models excel in tasks such as de novo peptide sequencing, identifying microorganisms, and discovering novel peptides, with implications for personalized medicine, cancer immunology, and beyond.
SourceTechnical University of Denmark·JournalNature Machine Intelligence·DateMar 31, 2025
Researchers have identified new gateways for drugs to modulate proteins regulating cellular activity. These discoveries may facilitate the creation of new medications or improve existing ones, leading to more targeted therapies and reduced side effects.
SourceIMIM (Hospital del Mar Medical Research Institute)·JournalNature Communications·DateMar 27, 2025
Researchers at the University of Houston College of Pharmacy have identified a potential therapeutic target to repair injured muscles. They discovered that fibroblast growth factor–inducible 14 (Fn14) plays a crucial role in regulating satellite cell stability and function, which are responsible for muscle growth, repair, and regenerat...
SourceUniversity of Houston·JournalJCI Insight·DateMar 26, 2025
Davis Instruments Vantage Pro2 Weather Station
Davis Instruments Vantage Pro2 Weather Station offers research-grade local weather data for networked stations, campuses, and community observatories.
Researchers at University of Illinois Chicago developed a powerful new antibiotic, Lariocidin, which targets ribosomes to prevent bacterial protein production. Its unique structure allows it to evade common bacterial defenses and transporters, making it a promising candidate for treating deadly infections.
SourceUniversity of Illinois Chicago·JournalNature·DateMar 26, 2025
Researchers at Osaka Metropolitan University developed an engineered yeast that can produce record-high yields of D-lactic acid from methanol, a key compound used in biodegradable plastics and pharmaceuticals. The optimized yeast strain achieves a 1.5-fold boost in production compared to other methanol-based methods.
SourceOsaka Metropolitan University·JournalBiotechnology for Biofuels and Bioproducts·TypeExperimental study·DateMar 20, 2025
Researchers isolated three potent anti-HIV compounds from Daphne pseudomezereum, with EC₅₀ values around 1 nM and IC50 > 5 μM. The findings suggest a promising approach to developing novel drugs with superior anti-HIV activity.
SourceToho University·JournalPhytochemistry·TypeObservational study·DateMar 20, 2025
A recent study identifies 11 natural compounds that can inhibit the SARS-CoV-2 spike protein, including caffeine, which exhibits high binding stability and excellent solubility. The discovery highlights the potential of natural products in combating COVID-19 and demonstrates the versatility of widely known compounds like caffeine.
SourceNara Institute of Science and Technology·JournalScientific Reports·TypeComputational simulation/modeling·DateMar 20, 2025
The Alliance for Genomic Discovery has completed sequencing 250,000 whole genomes, providing a comprehensive clinical genomic dataset. This data is being leveraged to accelerate drug target discovery and therapeutic research.
Apple AirPods Pro (2nd Generation, USB-C)
Apple AirPods Pro (2nd Generation, USB-C) provide clear calls and strong noise reduction for interviews, conferences, and noisy field environments.
Researchers at the University of Zurich have developed a technology to test 25 antibodies simultaneously in a single mouse, greatly reducing the number of laboratory animals required. The method uses protein fragments as barcodes for analysis, allowing for high-quality preclinical data on multiple antibody candidates.
SourceUniversity of Zurich·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateMar 18, 2025
The study found that tunneling nanotube-like structures connect cells in the heart, enabling long-distance intercellular communication essential for heart formation. Disruption of these structures resulted in impaired ventricular wall morphogenesis and defective myocardial growth.
Researchers from IOCB Prague have developed a compound that could treat alopecia areata by targeting the immune system. The substance, a series of prodrugs based on derivatives of itaconic acid, has shown efficacy in mice tests and may be administered orally.
SourceInstitute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB Prague)·JournalJournal of Medicinal Chemistry·DateMar 13, 2025
Insilico Medicine has secured a $110 million Series E financing to accelerate the advancement of its AI-driven drug discovery pipeline and platform developments. The funds will focus on refining AI models and algorithms, as well as advancing clinical validation of its flagship candidate for idiopathic pulmonary fibrosis treatment.
Apple MacBook Pro 14-inch (M4 Pro)
Apple MacBook Pro 14-inch (M4 Pro) powers local ML workloads, large datasets, and multi-display analysis for field and lab teams.
Dr. Ronald Newbold has been appointed as the permanent CEO of Empire Discovery Institute (EDI), a non-profit drug discovery and development accelerator. With over 30 years of business development experience, Dr. Newbold will lead EDI's growth and expansion, including the addition of new programs and partnerships.
SourceEmpire Discovery Institute, Inc.·TypeNews article·DateMar 11, 2025
Scientists at Sanford Burnham Prebys discovered novel fragments of future drugs that selectively inhibit the enzyme VHR, which plays a role in controlling the immune system's response to danger. The findings may lead to the development of new therapies for sepsis and septic shock.
SourceSanford Burnham Prebys·JournalACS Omega·TypeExperimental study·DateMar 11, 2025
A new study reports that Raman spectroscopy, a noninvasive technique, can distinguish between abnormal FCD type II tissue and healthy brain cells with remarkable accuracy. This method could provide real-time guidance for surgeons to more accurately identify and remove affected tissue during surgery.
SourceSPIE--International Society for Optics and Photonics·JournalBiophotonics Discovery·DateMar 11, 2025
Rentosertib, a breakthrough drug candidate for idiopathic pulmonary fibrosis (IPF), has been granted an official generic name by the USAN Council. The drug's development was accelerated using generative AI, identifying TNIK as a promising target and designing small-molecule compounds in just 18 months.
The Aligning Science Across Parkinson’s (ASAP) initiative offers funding of up to $6M for research community members to develop sustainable tools for Parkinson’s disease research. The funding supports the development of preclinical models, detection reagents, and modulation agents to accelerate therapeutic research.
SourceAligning Science Across Parkinson's·DateMar 5, 2025
Sony Alpha a7 IV (Body Only)
Sony Alpha a7 IV (Body Only) delivers reliable low-light performance and rugged build for astrophotography, lab documentation, and field expeditions.
Insilico Medicine has deployed the first bipedal humanoid AI scientist, Supervisor, to aid in data acquisition and generation for training embodied AI systems. The humanoid will assist with lab tours, telepresence, tracking, and supervision, bridging the gap between human-free fully-autonomous robotics facilities.
Researchers have developed a palladium-mediated reaction to precisely modify peptides and proteins, overcoming challenges in bioconjugation. The method targets dehydroalanine-containing peptides and proteins, enabling efficient synthesis of structurally unique peptides.
SourceNational University of Singapore·JournalJournal of the American Chemical Society·TypeExperimental study·DateFeb 27, 2025
A new study discovered rare gene variants in Asian Indian people that increase the risk of Type 2 diabetes, providing a window into targeted treatment. The findings suggest that these variants can be used to create personalized medications that target specific proteins or pathways.
SourceUniversity of Oklahoma·JournalCommunications Medicine·TypeObservational study·DateFeb 26, 2025
Researchers from NUS have pioneered a new catalytic transformation that converts epoxides into fluorinated oxetanes, a coveted class of drug molecules. The discovery potentially opens the door to new medicines and offers a reliable route to incorporate these motifs into the design of novel small-molecule therapeutics.
SourceNational University of Singapore·JournalNature Chemistry·TypeExperimental study·DateFeb 21, 2025
DJI Air 3 (RC-N2)
DJI Air 3 (RC-N2) captures 4K mapping passes and environmental surveys with dual cameras, long flight time, and omnidirectional obstacle sensing.
The collaboration aims to accelerate antibody discovery and development using Harbour BioMed's technology platform and Insilico's AI expertise. The companies will develop next-generation AI-powered antibodies for immunology, oncology, and neuroscience, aiming to deliver innovative therapies with enhanced specificity, efficacy, and safety.
Researchers at Salk Institute discover SSRIs like Prozac regulate immune response, preventing sepsis in mice. The findings suggest a potential new use for the popular drug, which could lead to life-saving treatments and enhanced global preparedness for pandemics.
SourceSalk Institute·JournalScience Advances·DateFeb 14, 2025
Donald Patrick McDonnell, a professor at Duke University School of Medicine, has been awarded the Endocrine Society's John D. Baxter Prize for his research on hormone therapies for treating breast and prostate cancers. His work led to the discovery of novel treatments for these cancers and has improved patient care.
PairMap overcomes limitations of traditional methods by introducing intermediate compounds to predict binding affinities with high accuracy. The approach minimizes calculation errors, improves convergence, and reduces computational costs for complex transformations.
SourceInstitute of Science Tokyo·JournalJournal of Chemical Information and Modeling·TypeExperimental study·DateFeb 4, 2025
Sky-Watcher EQ6-R Pro Equatorial Mount
Sky-Watcher EQ6-R Pro Equatorial Mount provides precise tracking capacity for deep-sky imaging rigs during long astrophotography sessions.
ApoB100 protein structure revealed for the first time, allowing for more precise testing and treatment of high cholesterol and heart disease. The discovery may lead to new drugs targeting LDL particles, reducing side effects of statin drugs.
SourceUniversity of Missouri-Columbia·JournalNature·DateFeb 3, 2025
Researchers created a new biologic compound using protein engineering to maximize therapeutic effects while reducing toxicity. The modified enzyme effectively destroyed leukemia cells in mice without common side effects, shrinking tumors in additional cancer models.
A new method of testing the metabolic effects of thousands of active substances at the same time has been developed by researchers at the University of Basel, providing valuable insights into the modes of action of known medications. The study reveals previously unknown mechanisms and potential side effects.
SourceUniversity of Basel·JournalNature Biotechnology·DateJan 28, 2025
Rigol DP832 Triple-Output Bench Power Supply
Rigol DP832 Triple-Output Bench Power Supply powers sensors, microcontrollers, and test circuits with programmable rails and stable outputs.
Researchers at SickKids have identified the KCNB2 gene as a key target for treating medulloblastoma. Targeting this gene can enhance current cancer treatments and tackle tumour growth without impacting surrounding healthy cells.
SourceThe Hospital for Sick Children·JournalDevelopmental Cell·DateJan 24, 2025
Critical Path Institute's Translational Therapeutics Accelerator (TRxA) is launching its 2025 global Request for Proposals to support academic researchers in bridging the 'valley of death' in drug development. The program aims to enable the transition of innovative therapeutics from lab to patients.
The article reviews metabolomics-driven approaches for identifying therapeutic targets in drug discovery, highlighting the challenges and limitations of current methods. Emerging technologies like single-cell metabolomics, artificial intelligence, and mass spectrometry imaging are explored to enhance target discovery.
SourceSichuan International Medical Exchange and Promotion Association·JournalMedComm·DateJan 13, 2025
Fluke 87V Industrial Digital Multimeter
Fluke 87V Industrial Digital Multimeter is a trusted meter for precise measurements during instrument integration, repairs, and field diagnostics.
Researchers have identified a 177-gene signature common to metastasis across cancers, allowing for personalized risk assessment and potential therapies. The discovery could lead to broader treatment options, faster drug access, and improved patient outcomes.
SourceUniversity of Southern Denmark Faculty of Health Sciences·JournalMolecular Cancer·DateJan 9, 2025
Positive Phase 1 trial results suggest ISM5411's gut-restrictive property and favorable pharmacokinetic profile, validating its potential for treating inflammatory bowel disease. Insilico Medicine expects to initiate a Phase 2 proof-of-concept study in active ulcerative colitis patients.
A University of Oklahoma research team has developed a breakthrough method of adding a single nitrogen atom to bioactive molecules, transforming them into new pharmacophores. This process, called skeletal editing, could open up uncharted regions of chemical space in drug discovery, making existing drugs cheaper and more accessible.
SourceUniversity of Oklahoma·JournalScience·TypeExperimental study·DateJan 2, 2025
Researchers at MD Anderson Cancer Center have made significant breakthroughs in smoking cessation treatments, with a study finding that varenicline plus counseling is the most effective treatment for individuals with major depressive disorder. Additionally, a new radiotherapy technique demonstrates effectiveness in treating metastatic ...
SourceUniversity of Texas M. D. Anderson Cancer Center·DateDec 18, 2024
The study uses generative AI to identify and optimize potent and selective HPK1 inhibitors for immunotherapy. The results show a relatively balanced candidate compound with adequate in vitro ADME, in vivo PK properties, good oral bioavailability, and robust in vivo efficacy in various cancer models.
Aranet4 Home CO2 Monitor
Aranet4 Home CO2 Monitor tracks ventilation quality in labs, classrooms, and conference rooms with long battery life and clear e-ink readouts.
A team of researchers at USC will receive funding to test a novel approach to slowing age-related cognitive decline, targeting the brain's lymphatic system. The grant aims to delay the onset of Alzheimer's and Parkinson's disease by clearing waste buildup.
Insilico Medicine has received its first clinical milestone payment of $10 million from Exelixis for XL309, a selective USP1 inhibitor discovered with the company's AI platform. The drug is being developed for advanced solid tumors and has shown efficacy in preclinical studies.
SPACe enables researchers to analyze large datasets in an efficient way, capturing the full diversity of cellular responses. The platform provides a more nuanced understanding of how drugs interact with cells, revealing insights into mechanisms beyond cell death.
SourceBaylor College of Medicine·JournalNature Communications·TypeImaging analysis·DateDec 12, 2024
Insilico Medicine has nominated ISM8969, an orally available NLRP3 inhibitor, as a potential treatment for various inflammatory diseases. The compound has shown promising results in preclinical evaluation studies, including balanced druggability and efficacy against inflammation.
Insilico Medicine has successfully integrated cutting-edge generative AI models into its platform, achieving significant increases in accuracy and speed. The company's AI-powered solutions have shown promising results in preclinical candidates and Phase II clinical trials.
Nikon Monarch 5 8x42 Binoculars
Nikon Monarch 5 8x42 Binoculars deliver bright, sharp views for wildlife surveys, eclipse chases, and quick star-field scans at dark sites.
Insilico Medicine has developed an innovative platform using generative AI to discover novel molecules. The company has nominated over 20 preclinical candidates and received IND clearance for 10 molecules.
The new effort aims to rapidly transform academic breakthroughs into life-saving therapies for a range of medical conditions. Autobahn Labs will invest up to $5 million per selected project to support the development of new pharmaceuticals.
Insilico Medicine has received FDA clearance for ISM5939, a potential best-in-class oral small molecule inhibitor targeting ENPP1 for the treatment of solid tumors. ISM5939 demonstrated robust anti-tumor efficacy in preclinical studies and showed favorable safety profiles.
Researchers found neurotransmitters GABA and choline in the venom of estuarine and reef stonefish, which can modulate cardiovascular function. The discovery could aid in targeted treatments and venom-derived compound development for drug discovery.
GoPro HERO13 Black
GoPro HERO13 Black records stabilized 5.3K video for instrument deployments, field notes, and outreach, even in harsh weather and underwater conditions.
Argonne is using AI, high performance computing, simulation and structural biology to research novel ways to fight cancer and transform vaccine discovery. The lab aims to compress the drug discovery timeline and develop toolkits for broadly effective vaccines against multiple viral threats.
Researchers at New York University developed a mathematical approach, Crystal Math, to predict molecular crystal structures in hours, bypassing weeks or months of supercomputer processing. This breakthrough could speed up R&D for drugs and electronic devices.
SourceNew York University·JournalNature Communications·DateNov 14, 2024
The Phase IIa trial of ISM001-055 showed dose-dependent improvement in forced vital capacity (FVC) and percent predicted FVC, suggesting potential to slow or reverse disease progression. The treatment also demonstrated a favorable pharmacokinetics profile with minimal adverse events.